Abstract
Carcinoma of the urinary bladder (CB) is the second most common malignancy of the urinary tract. In Brazil there are about 3200 deaths per year resulting from this type of cancer. Currently, the main CB therapies include immunotherapy with BCG and chemotherapy. But the effectiveness of these therapies is low, have a high recurrence rate and several adverse effects. Thus, there is a demand…